Does Meloxicam Raise Blood Pressure?

Meloxicam can raise blood pressure, and the effect is not unique to this drug. As a nonsteroidal anti-inflammatory drug (NSAID), meloxicam shares a class-wide tendency to push blood pressure upward by interfering with how the kidneys handle sodium and fluid. The increase is typically modest in people with normal blood pressure, but it can be clinically meaningful if you already have hypertension or take blood pressure medication. The story gets more interesting when you look at how meloxicam compares to other NSAIDs, what the kidney is actually doing, and who should be most cautious.

Why NSAIDs Raise Blood Pressure in the First Place

The root of the problem is prostaglandins. These signaling molecules do many things throughout the body, but in the kidneys they help regulate blood flow, sodium excretion, and fluid balance. When you take an NSAID, the drug blocks cyclooxygenase (COX) enzymes that produce prostaglandins. With fewer prostaglandins circulating in the kidneys, your body starts retaining more sodium and water. Extra fluid in the bloodstream means more volume pressing against artery walls, which translates to higher blood pressure readings.

There is also a vascular component. Prostaglandins help blood vessels relax and dilate. When NSAID use suppresses prostaglandin production, blood vessels can constrict slightly, adding resistance that further nudges pressure upward. The combination of fluid retention and increased vascular resistance is what makes blood pressure effects a class property of NSAIDs rather than a quirk of any single drug.

Meloxicam is classified as a preferential COX-2 inhibitor, meaning it blocks the COX-2 enzyme roughly twelve times more than COX-1 in laboratory assays.¹ That selectivity is what gives meloxicam its reputation for being gentler on the stomach compared to older NSAIDs like ibuprofen or naproxen. But COX-2 is also the form of the enzyme that plays a major role in regulating kidney blood flow and sodium handling, which is why preferential COX-2 inhibition does not spare you from the blood pressure effect.

What Happens Inside the Kidney

Animal research has helped clarify exactly where meloxicam exerts its kidney effects. In studies using rats, meloxicam reduced blood flow to the outer medulla of the kidney, an area critical for concentrating urine and regulating sodium. This reduction happened in a dose-dependent fashion, and it occurred even when the animals were normally hydrated. When the animals were dehydrated (hypovolemic), the effects were worse.² The practical takeaway for people is that dehydration can amplify the kidney effects of meloxicam, making blood pressure increases more pronounced on hot days, during illness, or if you simply do not drink enough water.

This same research showed that meloxicam did not change overall mean arterial blood pressure in well-hydrated rats at the doses tested, even though medullary blood flow dropped. That fits what doctors tend to see in clinical practice: many people take meloxicam and never notice a blood pressure change on a single reading. The problem is cumulative. Over days and weeks, reduced kidney perfusion and subtle sodium retention can slowly push baseline blood pressure higher, especially when other risk factors are in play.

How Much Does Blood Pressure Actually Rise?

For the average person starting meloxicam, the blood pressure increase is usually in the range of a few millimeters of mercury. That sounds trivial, and for someone with normal blood pressure it often is. But if you already sit at the edge of hypertension, even a small bump can cross you into a range where your doctor might want to adjust treatment. And if you are already taking blood pressure medications, meloxicam can partially counteract their effects, particularly drugs that work through the kidneys such as ACE inhibitors, ARBs, and diuretics.

The effect varies from person to person. Some individuals see no measurable change, while others might see systolic pressure rise by five or more points. Age, kidney function, hydration status, salt intake, and the dose of meloxicam all influence the magnitude. Doctors sometimes describe NSAID-related blood pressure increases as “unmasking” a blood pressure tendency that was being kept in check by medications or lifestyle.

How Meloxicam Stacks Up Against Other NSAIDs

One of the most common questions people have is whether meloxicam is better or worse for blood pressure than ibuprofen, naproxen, or diclofenac. A pooled analysis of more than 27,000 patients found that meloxicam, at doses between 7.5 and 30 milligrams, was not associated with a higher incidence of hypertension, edema, or congestive heart failure compared to other NSAIDs as a group.³ In other words, meloxicam appears to carry roughly the same blood pressure baggage as the rest of the NSAID class, not more and not clearly less.

That finding aligns with what most rheumatologists observe in practice. Meloxicam’s advantage over traditional NSAIDs is mainly gastrointestinal: fewer stomach ulcers and less GI bleeding. On the cardiovascular and renal side, the differences between individual NSAIDs are more about degree than about whether an effect exists at all. Every NSAID on the market can raise blood pressure to some extent, and no NSAID has been shown to be completely free of this effect.

Naproxen often gets described as the “safest” NSAID for the heart, and there is some evidence to support that reputation when it comes to heart attack risk specifically. But for blood pressure specifically, naproxen is not dramatically different from its peers. The honest reality is that if blood pressure is your primary concern, all NSAIDs deserve caution.

Meloxicam and Heart Attack Risk

Blood pressure is not the only cardiovascular concern with meloxicam. A population-based study looking at heart attack risk found that current meloxicam users had about a 38 percent higher odds of myocardial infarction compared to people who had used NSAIDs in the past but were not currently taking them. Current diclofenac users showed a similar elevation at 37 percent, while naproxen users had a smaller and statistically non-significant increase of about 12 percent.⁴

These numbers require some context. An observational study like this can show associations but cannot prove that meloxicam directly caused the heart attacks. People who take meloxicam tend to have more arthritis, more inflammation, and more comorbidities than people who do not, and those factors themselves raise cardiovascular risk. Still, the pattern is consistent with what we know about COX-2 inhibition: by shifting the balance between molecules that promote clotting and those that prevent it, COX-2-preferential drugs can tip the scales toward clot formation. Blood pressure elevation is likely one contributing pathway among several.

The earlier pooled analysis of over 27,000 patients did not find an increased risk of heart attack with meloxicam compared to other NSAIDs, which suggests the absolute risk increase is modest and may be shared across the class rather than being a meloxicam-specific problem.³ For readers worried about heart risk, the takeaway is that meloxicam’s cardiovascular profile is broadly typical of its drug class, not dramatically safer or more dangerous than the average NSAID.

Who Should Be Most Careful

Certain groups face outsized risk from any NSAID-related blood pressure bump. If you fall into any of the following categories, the conversation with your doctor about meloxicam becomes more urgent:

Existing hypertension: If your blood pressure is already elevated or controlled by medication, meloxicam can undermine that control. You may need more frequent monitoring or a dosage adjustment in your blood pressure drugs.
Chronic kidney disease: Reduced kidney function means less capacity to handle the sodium-retaining effects of NSAIDs. Interestingly, one population-based study found that the risk association between meloxicam and chronic kidney disease was not significantly changed by whether or not the person had hypertension or diabetes, suggesting the kidney effect operates somewhat independently of those conditions.⁵
Heart failure: Even mild fluid retention can worsen symptoms in people whose hearts already struggle to pump effectively.
Older adults: Kidney function declines with age, often silently, making older people more susceptible to the renal effects of NSAIDs even when their blood work looks reasonable.
People taking certain drug combinations: If you take an ACE inhibitor or ARB plus a diuretic, adding an NSAID creates the so-called “triple whammy” combination that sharply increases the risk of acute kidney injury and blood pressure destabilization.

For people in these groups, the question is not really whether meloxicam can raise blood pressure but whether the pain relief it offers justifies the cardiovascular trade-off. Often, the answer involves using the lowest effective dose for the shortest possible time, a principle that applies to all NSAIDs.

Practical Steps for Monitoring

If you and your doctor decide meloxicam is the right choice for your arthritis or other inflammatory pain, a few practical steps can minimize the blood pressure impact. Getting a baseline blood pressure reading before starting the drug gives you a reference point. Rechecking after one to two weeks of regular use is a reasonable timeline, because the sodium-retention effect typically takes several days to accumulate. Home blood pressure monitors make this easy to track without extra office visits.

Staying well hydrated matters more than many people realize. As the animal research showed, dehydration amplifies the kidney effects of COX-2 inhibition.² That does not mean you need to force water, but it does mean paying attention to intake during hot weather, exercise, or illness when fluid losses increase. Moderating salt intake is also sensible, because the drug is already pushing your kidneys to hold onto sodium, and a high-salt diet compounds the problem.

If you notice your blood pressure climbing or your ankles swelling, those are signals to contact your prescriber rather than simply pushing through. Swelling is a visible sign of the same fluid retention that drives the blood pressure increase, so it serves as an early warning.

Why Meloxicam Gets Prescribed Despite the Risks

Given all this, you might wonder why doctors prescribe meloxicam at all. The answer lies in the balance sheet. For people with osteoarthritis or rheumatoid arthritis, chronic pain erodes quality of life, disrupts sleep, limits physical activity, and carries its own cardiovascular consequences (inactivity and chronic inflammation both raise heart risk independently). Meloxicam offers once-daily dosing, which improves adherence compared to drugs like ibuprofen that need to be taken three or four times a day. And its COX-2 selectivity means meaningfully fewer GI complications, which is a genuine advantage for long-term users.¹

For many arthritis patients, the realistic alternatives are not “no drug,” they are “a different NSAID” or “an opioid or corticosteroid with its own side-effect profile.” Acetaminophen (Tylenol) does not raise blood pressure but is significantly weaker as an anti-inflammatory and carries liver risks at higher doses. Topical NSAIDs (diclofenac gel, for instance) deliver less drug systemically and have smaller blood pressure effects, but they work best for localized joint pain and are less practical for widespread inflammation. The choice often comes down to which set of trade-offs fits the individual patient best.

Common Misconceptions About Meloxicam and Blood Pressure

One persistent myth is that because meloxicam is a prescription NSAID, it must be “stronger” and therefore more dangerous for blood pressure than over-the-counter options like ibuprofen. The prescription status has more to do with the drug’s COX-2 selectivity profile and dosing schedule than with any special cardiovascular hazard. As the pooled analysis showed, meloxicam’s rates of hypertension and edema were not higher than those seen with nonselective NSAIDs.³

Another misconception is that meloxicam raises blood pressure only while you are actively taking it and that the effect vanishes the instant you stop. The blood pressure increase does reverse after discontinuation, but it may take several days to a week for retained sodium and fluid to clear. People who stop and restart frequently can experience repeated cycles of fluid loading and unloading, which is not ideal for the cardiovascular system either.

A third misunderstanding surrounds the relationship between dose and blood pressure. Some people assume that because their doctor prescribed a low dose (7.5 mg), they are safe from blood pressure effects. In reality, even lower doses retain enough COX-2 inhibition to affect kidney prostaglandin production. Higher doses make the effect more likely and more pronounced, but they do not introduce a qualitatively different mechanism. If you are sensitive to the renal effects, even the standard low dose can matter.

The “Triple Whammy” Drug Interaction

One scenario that deserves its own discussion is the combination of an NSAID, a renin-angiotensin system blocker (ACE inhibitor or ARB), and a diuretic. This trio is sometimes called the “triple whammy” because each drug independently affects kidney perfusion or fluid balance, and together they can sharply raise the risk of acute kidney injury. The NSAID component of this combination reduces prostaglandin-mediated blood flow to the kidney. The ACE inhibitor or ARB dilates the outflow vessel from the kidney’s filtering unit, reducing the pressure that drives filtration. The diuretic depletes fluid volume, leaving less blood flow to go around.

Meloxicam is no exception to this risk. If you are already on an ACE inhibitor plus a water pill for blood pressure, adding meloxicam creates the very combination that guidelines flag as high-risk. In this situation your doctor may suggest alternative pain management, closer lab monitoring of kidney function (creatinine and potassium), or a temporary pause on one of the blood pressure medications while you use the NSAID short-term. The point is not that meloxicam is uniquely dangerous here, but that it plugs into a well-known hazardous drug combination just as readily as ibuprofen or diclofenac would.

When Timing and Duration Matter

How long you take meloxicam matters as much as whether you take it. A few days of use for an acute flare is a very different proposition from months of daily use for chronic arthritis. Short courses rarely produce clinically important blood pressure changes in otherwise healthy people, because the body’s compensatory mechanisms (increased natriuretic peptides, pressure-natriuresis adjustments) can usually handle a brief disruption. Chronic use is where problems accumulate: sustained sodium retention, gradual loss of kidney autoregulatory capacity, and progressive undermining of blood pressure medications.

There is also some evidence across the NSAID class that the first few weeks of use carry a disproportionate share of cardiovascular events, possibly because the body is adjusting to a sudden shift in prostaglandin balance. This is another reason doctors recommend starting at the lowest dose and paying closest attention to blood pressure and symptoms during the initial period of use. If a month of meloxicam passes without meaningful blood pressure changes and with good pain relief, the ongoing risk for that individual is likely lower than the initial period suggested.